XtalPi Holdings Limited 2228

XtalPi (HKEX: 2228), an AI- and robotics-driven drug and materials discovery company, today announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for KQTD-126. Developed internally, the candidate is a potential first-in-class gut-restricted pan-tropomyosin receptor kinase (pan-TRK) inhibitor designed to treat chronic intestinal pain associated with irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD).

XtalPi (HKEX: 2228) announced that Viva-Thera, a biotechnology company it incubated and backs as a strategic shareholder, has nominated a preclinical candidate (PCC) targeting the membrane-proximal external region (MPER) of HIV-1 gp41. The partners completed discovery and optimization in seven months by combining Viva-Thera's atomic-resolution structural research with XtalPi's AI drug design and automation platform.

Apex Intelligence has completed its angel and angel-plus funding rounds, raising nearly US$50 Million in total. The angel round was co-led by IDG Capital, LinkX Capital and XtalPi, with participation from Decent Capital, SEE Fund, Monad Ventures, and Winsoul Capital. The angel-plus round was co-led by Zhongguancun Science City Fund, SCGC, and Shanghai Engine Fund.

XtalPi Holdings Limited ("XtalPi", or the "Company") (HKEX: 2228), an innovative research platform company powered by artificial intelligence (AI) and robotics, announced that it will report its interim results for the six months ended June 30, 2026 on Wednesday, August 19, 2026, after the Hong Kong market closes.

XtalPi Holdings (SEHK:2228) has drawn fresh attention after recent trading left the stock down about 18% over the past month and about 26% over the past 3 months, despite a HK$7.04 last close. See our latest analysis for XtalPi Holdings. That recent slide sits against a wider picture where the 1-year total shareholder return is 15.6%, while the year-to-date share price return is down 29.53%. This suggests momentum has recently weakened as investors reassess growth and risk. If you are...

XtalPi stands to receive further payments based on clinical and commercial milestones, as well as future royalties.

XtalPi (2228.HK), a leading platform in artificial intelligence (AI) and robotics-driven drug discovery, today announced a strategic partnership with a prominent international biopharmaceutical company. The collaboration focuses on developing a best-in-class small molecule against a G protein-coupled receptor (GPCR). This agreement builds upon a rigorous and successful pilot phase, where XtalPi's integrated quantum physics and AI algorithms delivered breakthrough hit rates, confirming the platfo

XtalPi (2228.HK), an AI- and robotics- powered drug discovery platform, announced that its strategic collaboration with innovative biopharmaceutical company DoveTree Medicines Unus Inc. has achieved substantial progress, and that XtalPi has received the second payment under the agreement.

XtalPi (2228.HK), a leading AI- and robotics-powered innovation platform, today announced dual breakthroughs in its strategic partnership with PharmaEngine (4162.TWO) PEP08, a next-generation PRMT5 inhibitor discovered via XtalPi's platform, has successfully begun enrollments in a Phase I solid tumor trial, achieving a new clinical milestone. Built upon the success of PEP08 at the drug discovery stage, the two companies initiated a second project, targeting a different undisclosed synthetic leth

XtalPi Holdings Limited ("XtalPi", or the "Company") (HKEX: 2228), a leading global technology company in integrating artificial intelligence (AI) and robotics for drug and materials discovery, announced that it will report its annual results for the full year ended December 31, 2025 on Wednesday, March 25, 2026, after the Hong Kong market closes.

XtalPi Holdings (SEHK:2228) drew investor focus after saying it expects at least CN¥100 million in net profit for 2025. This marks a turnaround from the prior year’s loss, supported by financial asset gains and revenue growth. See our latest analysis for XtalPi Holdings. At a share price of HK$10.06, XtalPi’s 1 day share price return of 3.39% contrasted with a 30 day share price return decline of 10.82%, while the 1 year total shareholder return of 49.70% points to stronger longer term...

XtalPi, a global leading AI- and robotics-driven drug discovery platform, today noted a key milestone in its collaboration with ReviR Therapeutics: dosing of the first participant in the Phase 1 clinical trial of RTX-117, an investigational small molecule being developed for Charcot-Marie-Tooth disease (CMT) and Vanishing White Matter disease (VWM). The candidate, discovered and optimized using XtalPi's AI + robotics platform alongside ReviR Therapeutics' VoyageR AI platform, has also received U